GL

Globe Life Inc

Add to Watchlist

Advanced Chart

123.600

+0.640(+0.520%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

124.755

Open

123.580

VWAP

123.47

Vol

487.29K

Mkt Cap

10.29B

Low

122.290

Amount

60.17M

EV/EBITDA(TTM)

8.68

Total Shares

92.27M

12.81B

EV/OCF(TTM)

9.13

P/S(TTM)

1.91

Globe Life Inc. is an insurance holding company. The Company's primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The Company offers Medicare Supplement and limited-benefit supplemental health insurance products that include accident, cancer, critical illness, heart, and intensive care products. These products are designed to supplement health coverage that applicants already own. Medicare Supplements are offered to enrollees in the traditional fee-for-service Medicare program. Medicare Supplement plans are standardized by federal regulation and are designed to pay deductibles and co-payments not paid by Medicare. It has four segments: life insurance, supplemental health insurance, annuities and investments. Life insurance segment’s products include traditional whole life and term life insurance.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

1.52B

+4.63%

3.503

+0.38%

1.51B

+4.66%

3.388

+14.07%

1.49B

+4.97%

3.239

+16.52%

Estimates Revision

The market is revising Upward the revenue expectations for Globe Life Inc. (GL) for FY2025, with the revenue forecasts being adjusted by 0.75% over the past three months. During the same period, the stock price has changed by 1.64%.

Revenue Estimates for FY2025

Revise Upward

+0.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.61%

In Past 3 Month

Stock Price

Go Up

+1.64%

In Past 3 Month

10 Analyst Rating

10.92% Upside

Wall Street analysts forecast GL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 137.10 USD with a low forecast of 117.00 USD and a high forecast of 168.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

5 Hold

0 Sell

Moderate Buy

10.92% Upside

Current: 123.600

Low

117.00

Averages

137.10

High

168.00

10.92% Upside

Current: 123.600

Low

117.00

Averages

137.10

High

168.00

Morgan Stanley

Nigel Dally

Hold

Maintains

$126 → $117

2025-04-10

Reason

Morgan Stanley

Nigel Dally

Price Target

$126 → $117

2025-04-10

Maintains

Hold

Reason

Morgan Stanley analyst Bob Huang lowered the firm's price target on Globe Life to $117 from $126 and keeps an Equal Weight rating on the shares. On average across the firm's life insurance coverage, Q1 EPS estimates declined 3% from prior estimates and its 2025 EPS estimates declined 4% from prior estimates, though results vary across companies, notes the analyst in a preview for the group. For underwriting-oriented companies that should not be as sensitive to equity market fluctuations, the firm's estimates generally did not change as much, but it still moved underwriter estimates down as they likely face an incrementally more challenging operating environment, the analyst noted.

Wells Fargo

Elyse Greenspan

Buy

Maintains

$141 → $140

2025-04-10

Reason

Wells Fargo

Elyse Greenspan

Price Target

$141 → $140

2025-04-10

Maintains

Buy

Reason

Wells Fargo lowered the firm's price target on Globe Life to $140 from $141 and keeps an Overweight rating on the shares. The firm notes that the quarter lost a little luster with the tariff backdrop and Wells thinks a bigger focus will be on any views of tariffs/ensuring macro backdrop.

JP Morgan

Jimmy Bhullar

Buy

Maintains

$136 → $145

2025-04-02

Reason

JP Morgan

Jimmy Bhullar

Price Target

$136 → $145

2025-04-02

Maintains

Buy

Reason

JPMorgan analyst Jimmy Bhullar raised the firm's price target on Globe Life to $145 from $136 and keeps an Overweight rating on the shares. The firm shifted its view on life insurance stocks from Positive to Neutral, saying risk/rewards "have become less compelling given an incrementally downbeat outlook for business fundamentals." It forecasts life insurers will report "weak" earnings and mixed business trends in Q1. JPMorgan reduced estimates as part of a Q1 earnings preview.

Piper Sandler

John Barnidge

Buy

Maintains

$140 → $152

2025-04-02

Reason

Piper Sandler

John Barnidge

Price Target

$140 → $152

2025-04-02

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Aflac (AFL) to $124 from $118 and keeps an Overweight rating on the shares. The firm is generally reducing EPS estimates for the group driven by fee and spread headwinds, and favors underwriting areas of lifecoland as a result. Fee businesses have client outflows, less fee and trading days and seasonally higher expenses. Spread has prospect of variable investment income normalization being pushed out, floater impact and possible negative commentary around prospective spread income expectations in Piper's opinion. The firm highlights Aflac and Globe Life (GL) among its Overweight names with both primarily focused on the underwriting portion of the industry.

Morgan Stanley

Nigel Dally

Hold

Maintains

$125 → $126

2025-02-28

Reason

Morgan Stanley

Nigel Dally

Price Target

$125 → $126

2025-02-28

Maintains

Hold

Reason

Wells Fargo

Elyse Greenspan

Buy

Maintains

$126 → $141

2025-02-19

Reason

Wells Fargo

Elyse Greenspan

Price Target

$126 → $141

2025-02-19

Maintains

Buy

Reason

Wells Fargo raised the firm's price target on Globe Life to $141 from $126 and keeps an Overweight rating on the shares. The firm updated estimates in the life insurance group post the Q4 reports. Wells left the Q4 earnings favoring the more defensive names within the life sector. Its top life idea is Unum Group (UNM).

See All Ratings

Valuation Metrics

The current forward P/E ratio for Globe Life Inc (GL.N) is 8.98, compared to its 5-year average forward P/E of 10.84. For a more detailed relative valuation and DCF analysis to assess Globe Life Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

10.84

Current PE

8.98

Overvalued PE

12.70

Undervalued PE

8.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

9.63

Current EV/EBITDA

8.38

Overvalued EV/EBITDA

11.20

Undervalued EV/EBITDA

8.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.83

Current PS

1.69

Overvalued PS

2.05

Undervalued PS

1.60